Fasoracetam

Fasoracetam is a synthetic nootropic discussed for calmer focus, social anxiety and changes in phenibut response. Reports range from useful calm to no effect, poor sleep or worse experiences, especially in complicated stacks and withdrawal histories. Community accounts do not establish safety or effectiveness.

What Fasoracetam is

• A racetam-family research compound, not a peptide. Fasoracetam is a synthetic small molecule also called NS-105 and AEVI-001. NFC-1 refers to the clinical development compound; the human study used fasoracetam monohydrate, while the FDA identity register separately lists anhydrous mappings. Official context Official context
• The GABA discussion needs careful reading. Users hope altered GABA-B brain signaling could change anxiety or phenibut tolerance. This does not demonstrate receptor recovery. Reddit r/Nootropics Personal report
• A receptor hypothesis is not a recovery test. A 1997 abstract reports more GABA-B receptors in rat brain tissue after repeated exposure. It does not show receptor recovery in people taking retail fasoracetam or establish a phenibut-withdrawal treatment. Animal context

Benefits people report

• Calmer attention and less social tension. Contributors describe easier focus, improved mood or less anxiety; one sublingual user reports help with attention and social anxiety. A different responder reports no sensation at all, so these accounts do not establish a dependable effect or treatment for ADHD. Reddit r/Nootropics
• Less anxiety does not necessarily mean better thinking. One recurring contributor reports calmer mornings while also exercising more and navigating a breakup. Another participant says performance on certain tasks felt worse; neither report measures learning or memory objectively. Reddit r/StackAdvice

The comparisons people make

• Phenibut-like feelings are not interchangeable effects. One user likens fasoracetam to a milder, cleaner-feeling phenibut; the warning-thread author instead describes phenibut feeling stronger and later poor experiences with fasoracetam. Those are subjective comparisons, not proof of equivalent pharmacology or a safe pairing. Reddit r/Nootropics Personal report
• Noopept and aniracetam appear as partners or alternatives. A combination post pairs fasoracetam with Noopept for focus and memory goals. A musician in the replies alternates fasoracetam or aniracetam within a larger stack; these accounts cannot rank the individual compounds or isolate their contributions. Reddit r/Nootropics

Doses people discuss

All amounts below are self-reports in milligrams (mg), not instructions. Product identity and labeled strength were not independently tested.

• Sublingual: 10–20 mg in specific reports. Sublingual means under the tongue. One contributor reports this band; an earlier post by the same handle describes 15 mg each morning. These are individual examples, not recommended amounts. Reddit r/Nootropics Reddit r/StackAdvice
• Swallowed caplets: 40 mg, then 100 mg and 120 mg on successive days. These are one Bluelight author’s later experiments after stopping phenibut, with kratom and other withdrawal factors still involved. They must not be merged with sublingual amounts into a dose ladder. Personal report
• 20–25 mg once or twice daily, route unspecified. Jack black reported these amounts across nearly a week before deciding to stop after a markedly worse week. This adverse account is not a safe-dose band. LongeCity
• Higher repeated amounts also appear, with an unspecified route. A six-week author eventually described 60 mg two or three times in an evening—120–180 mg across those administrations. This individual escalation does not establish a safe ceiling. LongeCity

Half-life: what the circulated number means

• About 2–3 hours is a forum claim. An Alpha GPC/fasoracetam exchange gives about two hours, then two to three hours, without a supporting measurement. That is circulating lore; half-life describes the decline of drug concentration, not the length of calm or the time needed to reverse tolerance. Reddit r/Nootropics

Onset: when a change is noticed

• About 40 minutes in a two-compound report. After 10 mg each of fasoracetam and Noopept under the tongue, the author described racing thoughts, tingling and warmth. This is a combined-exposure observation, not a clean fasoracetam onset or evidence of improved cognition. Reddit r/Nootropics
• A few days in a repeated-use account. The six-week author described unpleasant initial stimulation, then feeling more relaxed after two or three days. That change over repeated use is different from a single-dose onset. LongeCity

Duration: how long people feel a change

• At least three hours, or much of the day, in the same person’s reports. The daily-log contributor described at least three hours of feeling an effect plus an afterglow; their later comment says most of the day. These are the same person’s reports, not independent confirmation or a clearance measurement. Reddit r/StackAdvice Reddit r/Nootropics
• Reports after stopping are a separate question. The six-week author still described less anxiety over a week after stopping. That follow-up does not mean a single dose remains active for a week. LongeCity

Cycles and time off

• About a week with an occasional day off is documented. The daily-log author planned another two or three weeks, but a plan is not a completed course. No agreed break length emerges from these accounts. Reddit r/StackAdvice
• A six-week course is one person’s history. The LongeCity author stopped after that changing-dose period. Their preference for cycling does not establish a standard schedule or long-term safety. LongeCity
• An adverse course ended with a stopping decision. After nearly a week, jack black decided to stop following worsening anxiety and motivation, while acknowledging holiday events and setbacks. No subsequent recovery after stopping was documented in this thread. LongeCity
• An eight-week experiment was announced, not demonstrated. The Noopept combination author intended weekly updates across eight weeks. The inspected thread does not document that complete follow-up, so it cannot establish sustained benefit or tolerability. Reddit r/Nootropics

Good to know

• Activation, sleep problems and duller thinking belong in the account. Reports include early sleep difficulty and poorer perceived task performance; jack black ultimately described worse anxiety, procrastination and motivation and decided to stop. Holiday events, setbacks and co-use complicate causation; worsening is not evidence that someone needs to persist until receptors change. Reddit r/StackAdvice LongeCity
• A mixed overdose is a material caution. A published case describes severe sleepiness and a very slow heart rate after a reported 10 g of phenibut plus an unknown amount of fasoracetam, followed by hallucinations and psychiatric care. It cannot isolate fasoracetam’s role or establish a safe combination threshold. Official context
• Orphan designation is not approval. The FDA record lists fasoracetam monohydrate as designated for 22q11.2 deletion syndrome but not approved for that orphan indication. Neither that designation nor a research-product label verifies a retail product’s quality or supports self-treatment. Official context

What the community disagreements reveal

• The warning account changes with a complicated drug history. The seed author recalls earlier benefit, then poor experiences after phenibut-related problems while using gabapentin and benzodiazepines. Their description of “kindling” is an interpretation, not a confirmed mechanism; dismissing the symptoms because of co-use would also lose useful adverse information. Personal report
• A taper success story can be misread. Scrillion explicitly says fasoracetam was mostly absent during the successful phenibut taper, aside from one unhelpful trial amid multiple withdrawals. Later pleasant effects occurred after phenibut cessation, while kratom changes and agmatine remained in the picture; this is not evidence that fasoracetam enabled the taper. Personal report
• Keep a person’s revisions together. Jack black first reported no effect after two 20 mg administrations, then sleep disruption with alcohol and a stack involved, followed by tiredness. On July 10, 2017, after nearly a week at 20–25 mg once or twice daily, they reported markedly worse anxiety, procrastination and motivation and decided to stop, planning to replace it with DMAE. They also cited holiday social events and setbacks: this completes one adverse timeline without proving fasoracetam caused the deterioration. LongeCity
• A useful activity can have several contributors. The musician links a larger stack to focus, creativity and enjoyment while making music. Phenibut, caffeine and ALCAR were also present, and fasoracetam was sometimes replaced by aniracetam; attributing the entire experience to fasoracetam would overstate the report. Reddit r/Nootropics

What the human research can answer

• A selected early trial is not a general nootropic result. A 2018 study enrolled 30 adolescents with ADHD and selected glutamate-network variants. It used one fixed placebo week followed by four active weeks and reported improvement, but its small, single-blind design does not establish benefit for healthy adults or withdrawal treatment. Official context
• Later controlled results temper the early enthusiasm. In its ASCEND disclosure, the sponsor reported that the double-blind placebo-controlled trial did not meet the primary ADHD symptom endpoint in either part after six weeks. The early study should not be presented as the final clinical answer. Official context
• Measured oral half-life differs from the forum estimate. For single oral doses of 50, 100, 200, 400 and 800 mg, the study’s mean half-lives were respectively 4.44, 6.99, 4.48, 4.11 and 4.06 hours, with six participants per group. These are pharmacokinetic measurements, not community dose suggestions, felt duration or sublingual values. Official context
• Short monitored tolerability is a narrow finding. Headache, fatigue and gastrointestinal symptoms were reported during the study; the authors found no frequency difference between the placebo week and active weeks. That does not settle long-term use or mixed-drug risks outside the study. Official context